Analysts forecast that Patheon NV (NASDAQ:PTHN) will report $520.86 million in sales for the current fiscal quarter, according to Zacks. Seven analysts have issued estimates for Patheon NV’s earnings. The highest sales estimate is $530.00 million and the lowest is $502.70 million. Patheon NV posted sales of $482.00 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 8.1%. The firm is scheduled to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Patheon NV will report full-year sales of $520.86 million for the current fiscal year, with estimates ranging from $1.99 billion to $2.02 billion. For the next financial year, analysts expect that the company will post sales of $2.20 billion per share, with estimates ranging from $2.18 billion to $2.23 billion. Zacks’ sales averages are a mean average based on a survey of research firms that follow Patheon NV.

Patheon NV (NASDAQ:PTHN) last posted its quarterly earnings results on Thursday, June 8th. The company reported $0.20 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.19 by $0.01. The business had revenue of $483.40 million during the quarter, compared to analysts’ expectations of $466.08 million. The business’s quarterly revenue was up 3.2% compared to the same quarter last year.

PTHN has been the topic of a number of research reports. Zacks Investment Research raised shares of Patheon NV from a “hold” rating to a “buy” rating and set a $39.00 target price on the stock in a research note on Saturday, June 10th. Jefferies Group LLC downgraded shares of Patheon NV from a “buy” rating to a “hold” rating and raised their target price for the company from $32.00 to $35.00 in a research note on Tuesday, May 16th. Leerink Swann downgraded shares of Patheon NV from an “outperform” rating to a “market perform” rating and raised their target price for the company from $31.00 to $35.00 in a research note on Friday, June 9th. William Blair downgraded shares of Patheon NV from an “outperform” rating to a “market perform” rating in a research note on Monday, May 15th. Finally, Raymond James Financial, Inc. reissued a “market perform” rating and issued a $35.00 target price on shares of Patheon NV in a research note on Thursday, June 8th. Seven investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $34.50.

Patheon NV (PTHN) opened at 34.97 on Friday. The stock has a market cap of $5.08 billion and a PE ratio of 44.83. Patheon NV has a 1-year low of $23.72 and a 1-year high of $35.01. The stock has a 50 day moving average price of $34.92 and a 200 day moving average price of $31.47.

ILLEGAL ACTIVITY NOTICE: “Patheon NV (PTHN) Expected to Post Quarterly Sales of $520.86 Million” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/08/20/patheon-nv-pthn-expected-to-post-quarterly-sales-of-520-86-million.html.

Large investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. purchased a new stake in Patheon NV during the second quarter valued at about $119,000. Seven Eight Capital LP purchased a new stake in Patheon NV during the second quarter valued at about $136,000. Pacad Investment Ltd. purchased a new stake in Patheon NV during the second quarter valued at about $164,000. Utah Retirement Systems purchased a new stake in Patheon NV during the second quarter valued at about $212,000. Finally, Amalgamated Bank purchased a new stake in Patheon NV during the second quarter valued at about $222,000.

Patheon NV Company Profile

Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products.

Get a free copy of the Zacks research report on Patheon NV (PTHN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Patheon NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patheon NV and related stocks with our FREE daily email newsletter.